Three Chemotherapy To Suppress The Influence Of The Different Stages Of Cell Differentiation Of Myeloid Origin In Patients With Small Cell Lung Cancer

The research background:Lung cancer is the most common malignancy worldwide nowadays,Surgical therapy combined with chemotherapy to treat lung cancer is the mainway currently. But in fact, to the vast majority of lung cancer patients whocome to hospital or get clinical diagnosis or the first time, they has lost thechance of surgical treatment. And part of the patient, even if carried out surgery,there is still a high rate of metastasis and recurrence. Thus, we need a moreefficient method for treatment of lung cancer. In recent years, bio-immunotherapy is in clinical applications for tumor, it can improve the anti-tumor immunity in cancer patients. There is a close relationship between theimmune and tumor, lingering, immunization in one hand to play a certain rolein the formation of tumors. Such as the prevention of tumor formation and theformation of immune surveillance. But in the chronic inflammatory process dueto the immunological characteristics, of the myeloid suppressor cells, theprocess of myeloid suppressor cells involved in tumor immune suppression andimmune escape mechanism, this isone of the important factors affecting theimmune therapy.As the tumor microenvironment to delve deeply, theresearchers found that the proportion in the peripheral blood, and tissues ofmyeloid derived suppressor cells (MDSCs) in patients with tumors is higherthan the normal people, myeloid derived suppressor cells (MDSCs) involved inimmune suppression and immune escape, one of the main factors is that itinfluence the curative effects.Objective:There have been many studies about MDSCs, according to the surfacemarkers MDSCs can be divided into granulocyte and monocyte lineages, andfound different tumor types and distribution of myeloid derived suppressor phenotype cell number differences. It has been found that myeloid derivedsuppressor cells in all of the various types ofmalignant tumors in the abnormalaggregation, and it is closely related with the prognosis of the patients. Thisstudy is labeled CD14+/CD33+/CD11b+antibody on MDSCs, using flowcytometry detect the percentage of Monocyte and granulocyte in peripheralblood of the III, IV stage patients with small cell lung cancer before and afterchemotherapy Analysis of the effect of different chemotherapy regimens forsmall cell lung cancerpatients with different stages of myeloid derivedsuppressor cells differentiation, wondering that if chemotherapy and prognosiscollate each other and explore its clinical significance.Method:1.selected80cases of patients with small cell lung cancer IIIstage, IVstage of different chemotherapy regimens, in the respiratory department of Jilinprovince Changchun City, Japan Union Hospital of Jilin University from2013October-2014November The pathological diagnosis of small cell carcinomahave been clear. Divided into eight groups, each group of10people, selected10cases of normalhealthy people. These people unified code intoA, B, C, D, E,F, G, H, I. A, B in these groups, C, G in patients with stage III, D, E, as, F, Hfor the IV period, I group for the healthy people, A, D two groups for the EPprogram; B, E two groups for the TP program; C, F two groups havecontraindication to chemotherapy; G, H two groups of TP+EP.2.the collection of these human peripheral blood, application of CD11b+, CD14+, CD33+mark on their blood cells, which were detected by flowcytometry, analyze the content of before and after treatment in patients withtumors of the myeloid derived suppressor cells, content analysis of myeloidderived suppressor cells in healthypopulation. Finally the collected data weresummarized Chi square test and t test test the gathering data, and use mean±SDstatistically quantified on these data. And the statistical results were comparedto determine the myeloid derived suppressor cells and small cell lung cancer,the relationship between myeloid derived suppressor cells and EPchemotherapy scheme, the relationship betweenmyeloid derived suppressorcells and TP chemotherapy, the relationship between the different stages ofsmall cell lung cancer with TP chemotherapy scheme, the relationship betweenthe different stages of small cell lung cancer with EPchemotherapy scheme, therelationship between TP regimen and EP regimen, the relationship betweenmyeloid derived suppressor cells and normal human.Results:1.The effect of EP in small cell lung cancer of stage III patients is obvious.2.The effect of TP regimen in small cell lung cancer of stage IV patients isobvious.3.Two schemes is combined, but there is no obvious numerical change.4.Through the comparison of myeloid derived suppressor cells of tumorpatients and normal human wen can obtain that the content of myeloid derivedsuppressor cells and tumor are closely linked(P<0.05). 5.Contrast the content of myeloid derived suppressor cells in patients aftertreatment and before treatment, we can obtain that chemotherapy is to achievethe control effect on small cell lung cancer by inhibiting the production ofmyeloid derived suppressor cells (P<0.05).6.To the choice of,TP scheme and the EP scheme, no matter what kind ofplan, they have an important role in inhibiting both inhibitory cell proliferationon medullary source(P>0.05).Conclusion:1.In small cell lung cancer of stage III patients and IV patients with EPchemotherapy will have more significant effect.2.The combined effect of two kinds of scheme is little.3.Myeloid derived suppressor cells.accounte for a larger proportion inpatients with tumor.4.Tumopatients with certain chemotherapy whose number of myeloidderived suppressor cells can reduced to close to normal population levels.